06:36:38 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-29 Bokslutskommuniké 2024
2024-10-29 Kvartalsrapport 2024-Q3
2024-07-30 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning ZICC 0.00 SEK
2024-04-29 Kvartalsrapport 2024-Q1
2024-01-26 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-06-21 Ordinarie utdelning ZICC 0.00 SEK
2023-06-20 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 Ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 Ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 Ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst versamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2023-05-26 14:20:00

New Ziccum Board member Assoc. Prof. Per Gerde has over 55 peer-reviewed scientific papers and six patent families to his name. He is the original inventor of Ziccum’s drying technology for pharmaceuticals, LaminarPace, and an authority on aerosol exposure technologies and inhalation toxicology. “Per brings decades of industry expertise to our Board, as well as his background knowledge of LaminarPace” says Ziccum Chairman Fredrik Sjövall, “we are delighted to welcome him”.

Per Gerde is Associate Professor of Inhalation Toxicology at the Division of Physiology, Institute of Environmental Medicine at Karolinska Institutet (retired, but remains associated), and the founder in 2004 of Inhalation Sciences AB (ISAB), Ziccum’s original parent company, for whom he remains CSO.

Gerde is a recognized authority in inhalation research and development and inhalation toxicology. His previous roles include research scientist at the Swedish National Institute of Occupational Health and postdoctoral fellow and visiting scientist at the influential Lovelace Respiratory Research Institute in New Mexico, USA. He is a Key opinion leader within inhalation and is the inventor of ISAB’s precision aerosol generation system PreciseInhale, which is installed at development and research facilities in Europe, the US and Asia.

Ziccum’s’ pharmaceutical drying system LaminarPace was first developed by Assoc. Prof. Gerde to generate dry powder micronized particles suitable for aerosolization in PreciseInhale. As LaminarPace’s unique ability to deliver dried, thermostable particles of even delicate biologics and biopharmaceuticals emerged, Inhalation Sciences decided to spin the technology out, in 2017, into the subsidiary Ziccum AB.

Today’s LaminarPace is the fourth generation, with extensive development work completed towards its scale out as a unique unit of pharmaceutical production, including advanced 3D modeling being carried out in partnership with the ICP Institute of Computational Physics at the Zurich University of Applied Sciences’s School of Engineering (ZHAW).

Assoc. Prof. Per Gerde: “I am pleased and excited to be involved again with LaminarPace. The technological development and progress Ziccum has made in advancing the system from its early iterations is impressive and exciting. I am very happy to see the extent of that progress, and to be able to return to and contribute once more towards the system’s development, as a Board member. I look forward to working with the Ziccum team”.

Ziccum Chairman of the Board Fredrik Sjövall: “Per brings decades of industry expertise and wisdom to our Board of Directors, as well as his significant background knowledge of LaminarPace. His expertise and commitment to developing successful new systems that add new value to their sector is powerful and proven. We are delighted to welcome him to the Board”.